Wolfgang H. Jost

Q: What Schools Are Affiliated With Wolfgang H. Jost

Wolfgang H. Jost is affiliated with the following schools: University of Freiburg, Columbia University

Wolfgang H. Jost's AcademicInfluence.com Rankings

Wolfgang H. Jost

Philosophy

#9226

World Rank

#12755

Historical Rank

Logic

#6213

World Rank

#7707

Historical Rank

philosophy Degrees

Wolfgang H. Jost

Biology

#12661

World Rank

#16152

Historical Rank

Neuroscience

#2137

World Rank

#2197

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Wolfgang H. Jost's Degrees

PhD Neuroscience University of Vienna
Doctorate Medicine University of Vienna

Why Is Wolfgang H. Jost Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Wolfgang H. Jost's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Vulnerability of the nigrostriatal system as detected by transcranial ultrasound (1999) (326)
A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia (2005) (250)
Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm (2006) (241)
One hundred cases of anal fissure treated with botulin toxin (1997) (220)
Nonmotor fluctuations in Parkinson disease (2013) (203)
Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. (2007) (180)
Striatal FP-CIT uptake differs in the subtypes of early Parkinson’s disease (2007) (158)
Early diagnosis of Parkinson’s disease (2006) (144)
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial (2017) (143)
Gastrointestinal Motility Problems in Patients with Parkinson’s Disease (1997) (140)
Is levodopa toxic? (2004) (131)
Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease. (2006) (126)
Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm (2001) (117)
Botulinum toxin: clinical use. (2006) (116)
FP‐CIT and MIBG scintigraphy in early Parkinson's disease (2005) (115)
Botulinum Neurotoxin Type A Free of Complexing Proteins (XEOMIN®) in Focal Dystonia (2012) (113)
Therapy of anal fissure using botulin toxin (1994) (106)
Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease (2007) (104)
Gastrointestinal dysfunction in Parkinson's Disease (2010) (97)
Treatment of drooling in Parkinson's disease with botulinum toxin (1999) (95)
Classification of posture in poststroke upper limb spasticity: a potential decision tool for botulinum toxin A treatment? (2012) (93)
A common mutation (ε1267delG) in congenital myasthenic patients of Gypsy ethnic origin (1999) (90)
Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX°) in healthy volunteers (2005) (83)
Autonomic dysfunctions in idiopathic Parkinson's disease (2003) (83)
Use of botulinum toxin in anal fissure (1993) (81)
The profile of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type A: an international survey (2010) (79)
Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapy (2012) (79)
Evidence-based medicine: botulinum toxin A in migraine and tension-type headache (2001) (76)
α-Synuclein in Parkinson’s disease: causal or bystander? (2019) (71)
Perianal thrombosis following injection therapy into the external anal sphincter using botulin toxin (1995) (59)
Botulinum toxin in the treatment of neurological disorders of the autonomic nervous system. (1999) (58)
Botulinum toxin treatment of secretory disorders (2004) (57)
Repeat Botulin Toxin Injections in Anal Fissure (In Patients with Relapse and After Insufficient Effect of First Treatment) (1999) (55)
Defecatory disorders in de novo Parkinsonians--colonic transit and electromyogram of the external anal sphincter. (1998) (55)
Botulinum toxin in therapy of anal fissure (1995) (54)
Quantitative assessment of non-motor fluctuations in Parkinson’s disease using the Non-Motor Symptoms Scale (NMSS) (2015) (50)
Nondipping in Parkinson's Disease (2011) (49)
The Parkinson–Control study: A 1‐year randomized, double‐blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease (2006) (49)
Lewy body dementia and Parkinson’s disease with dementia (2008) (49)
Utility of the WHO‐five well‐being index as a screening tool for depression in Parkinson's disease (2010) (48)
Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: a systematic review (2009) (46)
Long‐term results with cisapride in Parkinson's disease (1997) (45)
Eye movement in amyotrophic lateral sclerosis: a longitudinal study. (1995) (45)
Constipation in Parkinson's disease (1991) (45)
Relevance of sonography for botulinum toxin treatment of cervical dystonia: an expert statement (2014) (45)
SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea (2019) (44)
Duloxetine: mechanism of action at the lower urinary tract and Onuf’s nucleus (2004) (43)
A common mutation (epsilon1267delG) in congenital myasthenic patients of Gypsy ethnic origin. (1999) (42)
Nonmotor symptoms and focal cervical dystonia: Observations from 102 patients (2014) (40)
Ten years' experience with botulin toxin in anal fissure (2002) (40)
The phenylalanine loading test in the differential diagnosis of dystonia (2003) (39)
A new method to determine pudendal nerve motor latency and central motor conduction time to the external anal sphincter. (1993) (37)
Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm (2011) (36)
Constipation in idiopathic Parkinson's disease. (2003) (36)
Autonomic Disorders in Multiple Sclerosis (2011) (36)
Magnetic stimulation of the pudendal nerve (1994) (35)
Arrested cerebral adrenoleukodystrophy: a clinical and proton magnetic resonance spectroscopy study in three patients. (1996) (35)
Ropinirole, a non-ergoline dopamine agonist. (2006) (35)
Botulinum toxin: evidence-based medicine criteria in rare indications (2001) (35)
An open-label cohort study of the improvement of quality of life and pain in de novo cervical dystonia patients after injections with 500 U botulinum toxin A (Dysport) (2013) (35)
Urological problems in Parkinson’s disease: clinical aspects (2013) (34)
Advanced stages of PD: interventional therapies and related patient-centered care (2015) (33)
Functional outlet obstruction: anismus, spastic pelvic floor syndrome, and dyscoordination of the voluntary sphincter muscles. Definition, diagnosis, and treatment from the neurologic point of view. (1999) (33)
Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized‐controlled trial (2016) (32)
Selection of Muscles for Botulinum Toxin Injections in Cervical Dystonia (2015) (32)
Botulinum toxin in tension-type headache (2004) (31)
Depression in Parkinson’s disease (2001) (31)
The option of sonographic guidance in Botulinum toxin injection for drooling in Parkinson’s disease (2015) (30)
[Non-motor Symptoms Questionnaire and Scale for Parkinson's disease. Cross-cultural adaptation into the German language]. (2010) (29)
The effect of cisapride on delayed colonic transit time in patients with idiopathic Parkinson's disease. (1994) (29)
Differentiation of atypical Parkinson syndromes (2017) (29)
Parkinson’s disease between internal medicine and neurology (2015) (29)
Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders (2015) (28)
Importance of 123I-Metaiodobenzylguanidine Scintigraphy/Single Photon Emission Computed Tomography for Diagnosis and Differential Diagnostics of Parkinson Syndromes (2010) (28)
Influence of the Nonergot Dopamine Agonist Piribedil on Vigilance in Patients With Parkinson Disease and Excessive Daytime Sleepiness (PiViCog-PD): An 11-Week Randomized Comparison Trial Against Pramipexole and Ropinirole (2014) (27)
Efficacy and safety of botulinum toxin type A (Dysport) for the treatment of post-stroke arm spasticity: Results of the German–Austrian open-label post-marketing surveillance prospective study (2014) (27)
Anatomy and cervical dystonia (2017) (26)
Pramipexole Extended Release: A Novel Treatment Option in Parkinson's Disease (2010) (26)
Efficacy and tolerability of rasagiline in daily clinical use – a post‐marketing observational study in patients with Parkinson’s disease (2010) (26)
Current state of stem cell research for the treatment of Parkinson's disease (2002) (26)
Gastrointestinal involvement in Parkinson’s disease: pathophysiology, diagnosis, and management (2022) (25)
Duloxetine in the treatment of stress urinary incontinence (2005) (25)
Safinamide Add on to L-Dopa: A Randomized, Placebo-Controlled, 24-Week Global Trial in Patients with Parkinson's Disease (PD) and Motor Fluctuations (SETTLE) (P01.062) (2013) (25)
A botulinum toxin A treatment algorithm for de novo management of torticollis and laterocollis (2011) (25)
Dynamics of Parkinson’s Disease Multimodal Complex Treatment in Germany from 2010–2016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers (2019) (25)
Costs in the treatment of parkinsonism (2000) (24)
Botulinum toxin in patients with multiple sclerosis (2006) (24)
Severity of orthostatic hypotension in the course of Parkinson's disease: no correlation with the duration of the disease. (2015) (23)
Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson’s Disease Patients (2019) (23)
Autonome Regulationsstrungen beim Parkinson-Syndrom (1995) (22)
[Nonmotor symptoms in Parkinson's disease]. (2017) (22)
Colonic transit time in nonidiopathic Parkinson's syndrome. (1994) (22)
A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial (2020) (21)
Autonomic nervous system dysfunction in lightning and electrical injuries. (2005) (21)
Frequency of different subtypes of cervical dystonia: a prospective multicenter study according to Col–Cap concept (2019) (21)
Therapy of anal fissure using botulin toxin (1994) (21)
Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeks. (2019) (21)
Autonomic Dysfunction in Parkinson's Disease: Cardiovascular Symptoms, Thermoregulation, and Urogenital Symptoms. (2017) (21)
Therapy of Sialorrhea with Botulinum Neurotoxin (2019) (20)
Indirect meta-analysis of randomised placebo-controlled clinical trials on rasagiline and selegiline in the symptomatic treatment of Parkinson's disease (2012) (19)
Assessment of Nonmotor Fluctuations Using a Diary in Advanced Parkinson's disease. (2016) (18)
Botulinum toxin in multiple sclerosis (2006) (18)
Surface versus needle electrodes in determination of motor conduction time to the external anal sphincter (2004) (18)
Early Detection of Parkinson’s Disease: Unmet Needs (2008) (17)
SIAXI (2019) (17)
Hypersalivation: update of the German S2k guideline (AWMF) in short form (2019) (16)
Electrostimulation in fecal incontinence (1998) (16)
Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration (2014) (16)
Interkulturelle Adaptation des Survey of Autonomic Symptoms (SAS) (2012) (16)
[Therapy and care of patients with chronic migraine: expert recommendations of the German Migraine and Headache Society/German Society for Neurology as well as the Austrian Headache Society/Swiss Headache Society]. (2012) (16)
Autonomic disturbances including impaired hand thermoregulation in multiple system atrophy and Parkinson’s disease (2017) (15)
Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study (2020) (15)
[Characteristics and dynamics of inpatient treatment of patients with Parkinson's disease in Germany : Analysis of 1.5 million patient cases from 2010 to 2015]. (2019) (15)
Reduced Body Mass Index in Parkinson’s Disease: Contribution of Comorbid Depression (2013) (15)
Drug interactions in the treatment of Parkinson's disease (2002) (15)
Drug-induced impulse control disorders in Parkinson’s disease (2011) (15)
The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature (2021) (15)
Botulinum toxin in neuro‐urological disorders (2004) (15)
Shock Waves and Detonations in Gases (1968) (15)
[Clinical use of botulinum toxin]. (2008) (14)
[Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy]. (2007) (14)
Evidence-based medicine (EBM) (2001) (13)
Cervical dystonia - improving the effectiveness of botulinum toxin therapy. (2020) (13)
Timing and Kinetics of Nonmotor Fluctuations in Advanced Parkinson's Disease. (2017) (13)
Analyse der direkten Kosten in der Parkinson-Therapie (2003) (13)
EMG of the external anal sphincter: Needle is superior to surface electrode (2000) (13)
The challenge of pain in the pharmacological management of Parkinson’s disease (2019) (12)
A Pilot Prospective, Multicenter Observational Study of Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease (2015) (12)
Botulinum toxin type B in the treatment of anal fissures: First preliminary results (2001) (12)
Ropinirole: Current status of the studies (2004) (11)
Involuntary contractions of the striated anal sphincters as a cause of constipation (1998) (11)
“An essay on the shaking palsy” 200 years old (2017) (11)
[Depression in Parkinson's disease. Part 1: epidemiology, signs and symptoms, pathophysiology and diagnosis]. (2008) (11)
The impact of ropinirole on blood pressure and noradrenaline concentration after active orthostasis in Parkinsonian patients. (1998) (11)
[Parkinson's Disease at the Border Between Inpatient and Outpatient Care]. (2016) (11)
[Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment]. (2008) (10)
Intraindividual Variability of Nonmotor Fluctuations in Advanced Parkinson's Disease. (2015) (10)
King’s Parkinson’s Disease Pain Scale (2018) (10)
Influence of levodopa on orthostatic hypotension in Parkinson's Disease. (2020) (10)
Cerebral and Extracranial Neurodegeneration are Strongly Coupled in Parkinson’s Disease (2007) (10)
Individualized OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Clinician‐ and Patient‐Reported Satisfaction: Long‐Term Observational Results from the ASPIRE Study (2020) (9)
Management of Pain in Parkinson’s Disease (2020) (9)
Preferred muscles in cervical dystonia. (2020) (9)
Botulinum toxin in painful diseases (2003) (8)
An update on the recognition and treatment of autonomic symptoms in Parkinson’s disease (2017) (8)
Tau Imaging in the 4-Repeat-Tauopathies Progressive Supranuclear Palsy and Corticobasal Syndrome: A 11C-Pyridinyl-Butadienyl-Benzothiazole 3 PET Pilot Study. (2020) (8)
[Botulinum toxin in specific pain therapy]. (2003) (8)
[Gastrointestinal dysfunction in idiopathic Parkinson's disease]. (2012) (8)
[Prospective study of the direct and indirect costs of idiopathic Parkinson's disease]. (2006) (8)
Clinical studies with ropinirole in Parkinson’s disease and RLS (2006) (8)
[Hypersalivation - inauguration of the S2k Guideline (AWMF) in short form]. (2013) (7)
A tribute to Wilhelm H. Erb (2006) (7)
Improvement of SF-36 scores in cervical dystonia patients—Is there a treatment effect when evaluating subscales? (2014) (7)
Dyskinesia in multiple system atrophy and progressive supranuclear palsy (2019) (7)
[Pharmaceutical treatment of stress incontinence. New approaches via a direct effect of duloxetine on Onuf's nucleus]. (2004) (7)
[Urinary incontinence in patients with Parkinson syndrome]. (1996) (7)
Implications of dopaminergic medication withdrawal in Parkinson’s disease (2021) (7)
Injection into the Longus Colli Muscle via the Thyroid Gland (2019) (7)
Adult Spasticity International Registry Study: methodology and baseline patient, healthcare provider, and caregiver characteristics. (2017) (7)
Somatosensory evoked potentials of the pudendal nerve in penile hypoesthesia. (1998) (7)
[Electrophysiologic diagnosis in erectile dysfunction]. (1996) (7)
A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease (2022) (6)
Influence of botulinum toxin injections on the sphincteric compound muscle action potential of the external anal sphincter (1997) (6)
Efficacy and safety of botulinum neurotoxin type A free of complexing proteins (NT 201) in cervical dystonia and blepharospasm (2007) (6)
Incidence of anal fissure in nonselected neurological patients (1999) (6)
[Analysis of direct costs in therapy of Parkinson disease]. (2003) (6)
Therapeutic approaches to Lambert-Eaton myasthenic syndrome in the intra-individual comparison. (1991) (6)
Rasagilin im klinischen Alltag (2008) (6)
Drug interactions with selegiline versus rasagiline (2012) (6)
GBA-associated PD: chances and obstacles for targeted treatment strategies (2022) (6)
Effectiveness of botulinum neurotoxin type A injections in naïve and previously-treated patients suffering from Torti- or Laterocollis or -caput: Results from a German-Austrian open-label prospective post-marketing surveillance study (2019) (6)
Patients’ perspective on current treatment options for Parkinson’s Disease (2017) (6)
Torticaput versus Torticollis: Clinical Effects with Modified Classification and Muscle Selection (2019) (6)
Levodopa–entacapone–carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-world experience and practical guidance (2022) (6)
Equivalent doses of ropinirole and bromocriptine (1999) (6)
Tremor in Idiopathic Cervical Dystonia – Possible Implications for Botulinum Toxin Treatment Considering the Col-Cap Classification (2020) (6)
Differential diagnosis of parkinsonism: a head-to-head comparison of FDG PET and MIBG scintigraphy (2020) (6)
Dynamics of device-based treatments for Parkinson’s disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa–carbidopa intestinal gel, and deep brain stimulation (2019) (6)
[Therapy of anal fissure using botulinum toxin: perianal thrombosis as a complication]. (1995) (6)
[Diagnostic evaluation of the rectum and pelvic floor in chronic constipation]. (1999) (6)
Use of Botulinum Neurotoxin in Parkinson’s Disease: A Critical Appraisal (2021) (6)
Validity of the DESPAR questionnaire as a new screening tool for depression in Parkinson’s disease (2011) (5)
Low-dosed Botulinum Toxin A in the Prophylactic Management of Unilateral Migraine: A Randomized Double-blind Placebo-Controlled Crossover Study (2011) (5)
[Therapy of Hemifacial Spasm with Botulinum Toxin]. (2017) (5)
Urethrismus accounting for voiding disorder. (1998) (5)
[Disorders of eye movement in amyotrophic lateral sclerosis--report of 2 patients]. (1995) (5)
Botulinum Toxin A in Anal Fissure: Why Does It Work? (2004) (5)
What are the considerations for anti-hypertensive treatment in patients with Parkinson’s disease? (2020) (5)
Riddle of the sphincters in anal fissure (1995) (5)
Interkulturelle Adaption der AIMS in deutscher Sprache (2016) (5)
Initial experience with ropinirole PR (prolonged release) (2008) (5)
Bilateral Globus Pallidus Internus Deep Brain Stimulation in a Case of Progressive Dystonia in Mohr-Tranebjaerg Syndrome with Bilateral Cochlear Implants (2018) (4)
Botulinum Toxin in Low Back Pain (2003) (4)
Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus (2022) (4)
Dose per muscle in cervical dystonia: pooled data from seven movement disorder centres. (2021) (4)
[Sympathetic skin response in Parkinson syndrome]. (1995) (4)
A critical review of incobotulinumtoxinA in the treatment of chronic sialorrhea in pediatric patients (2021) (4)
High clinician- and patient-reported satisfaction with individualized onabotulinumtoxinA treatment for spasticity across several etiologies from the ASPIRE study (2020) (4)
[S1-Guideline for Diagnosis and Treatment of Erectile Dysfunction]. (2019) (4)
Assessing the burden of illness from cervical dystonia using the Toronto Western Spasmodic Torticollis Rating Scale scores and health utility: a meta-analysis of baseline patient-level clinical trial data (2014) (4)
[Intercultural adaptation of the AIMS in German language: A scale for abnormal involuntary movements]. (2016) (4)
[Long-term treatment of Lambert-Eaton syndrome by 3, 4 diaminopyridine]. (1992) (4)
[Hypersalivation - Update of the S2k guideline (AWMF) in short form]. (2019) (4)
[Practical use of continuous apomorphine infusion via pump]. (2017) (4)
Potential Biomarkers of Parkinson's Disease (2007) (4)
Medikamentöse Interaktionen in der Parkinson-Therapie (2003) (3)
Influence of electrostimulation on the sphincteric compound muscle action potential in fecal incontinence (1997) (3)
[Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study]. (2018) (3)
Neurography of the pudendal nerve in pudendal canal syndrome (1999) (3)
Botulinum Toxin in the Treatment of Migraine (2003) (3)
An updated calculator for determining levodopa-equivalent dose (2021) (3)
[Blood pressure and hormonal regulation in active and passive orthostasis]. (1995) (3)
Torticaput versus Torticollis: Clinical Effects with Modified Classification and Muscle Selection (2019) (3)
[Disorders of autonomic regulation in Parkinson syndrome]. (1995) (3)
Validierung des NMSQuest in deutscher Sprache (2009) (3)
[Blood pressure adaptation and hormone regulation in Parkinson patients following orthostasis]. (1996) (3)
OnabotulinumtoxinA Treatment in Adults with Spasticity Reduces Caregiver Burden: Results from the ASPIRE Study (2019) (3)
[Ergotamine-induced rectal lesions in asymptomatic patients]. (1994) (2)
Are heart rate responses reproducible in the tilt-table test? (1994) (2)
[Treatment of Sialorrhea with Botulinum Neurotoxin Type A - Consensus Practice Recommendations for Children and Adults]. (2022) (2)
Early Diagnosis in Parkinson's Disease (2010) (2)
[Electrophysiologic studies of fecal incontinence in the woman]. (1998) (2)
Classification and Diagnosis of Cervical Dystonia: Revived Call for Consensus (2022) (2)
[Depression in Parkinson's disease--Part 2: Therapy and management]. (2010) (2)
Cerebral and extracranial neurodegeneration are strongly coupled in Parkinson's disease (2008) (2)
[Practical Use of the Levodopa Pump]. (2016) (2)
‘Similar To’ Is Not ‘Identical With’, and ‘Identical With’ Is Not ‘The Same As’ (2015) (2)
Evaluating Opicapone as Add-on Treatment to Levodopa/DDCI in Patients with Parkinson’s Disease (2022) (2)
Duloxetine in the treatment of stress urinary (2005) (2)
[Bladder dysfunctions in encephalomyelitis disseminata--drug and interventional therapeutic options]. (1995) (2)
[The oral vitamin E tolerance test--an attempt at standardization]. (1999) (2)
[Pharmacological treatment of motor symptoms in Parkinson's diseases]. (2017) (2)
Commentary: Roles of the Cannabinoid System in the Basal Ganglia in Parkinson's Disease (2022) (2)
Poster session Sessions 32: Methods in electrophysiologyA new method to determine pudendal nerve motor latency and central motor conduction time to the external anal sphincter (1993) (2)
Randomized controlled trials on the use of cannabis-based medicines in movement disorders: a systematic review (2022) (2)
[Indirect costs in idiopathic Parkinson's disease]. (2005) (2)
Long‐Term Observational Results from the ASPIRE Study: OnabotulinumtoxinA Treatment for Adult Lower Limb Spasticity (2020) (2)
Comment: Relevance of sonography for botulinum toxin treatment of cervical dystonia: An expert recommendation (2016) (2)
[When should we start medical treatment in Parkinson disease]. (2010) (2)
Botulinum neurotoxin in cervical dystonia revisited - recent advances and unanswered questions. (2021) (2)
Diffusion microstructure imaging in progressive supranuclear palsy: reduced axonal volumes in the superior cerebellar peduncles, dentato-rubro-thalamic tracts, ventromedial thalami, and frontomesial white matter. (2022) (2)
Poster 361 Impact of Early Intervention with OnabotulinumtoxinA Treatment in Adult Patients with Post‐Stroke Lower Limb Spasticity (2016) (2)
[Therapy of Hemifacial Spasm with Botulinum Toxin]. (2019) (2)
Basal Ganglia – A translational journal (2011) (1)
Kindness in science does matter (2021) (1)
Parkinsonian Drugs: Indications (2020) (1)
[The history of Freezing-of-gait in Parkinson's disease - from phenomena to symptom]. (2020) (1)
[Clinical data of the prolonged-release formulation of ropinirole]. (2010) (1)
Time for a new definition of Parkinson’s disease (2019) (1)
[Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease]. (2018) (1)
The botulinum toxin legend of Reinhard Heydrich's death (2017) (1)
Is cardiovascular dysregulation in idiopathic Parkinson's syndrome correlated with decreased hormonal release?; TO THE EDITOR (1997) (1)
Treadmill training and physiotherapy similarly improve dual task gait performance: a randomized-controlled trial in Parkinson’s disease (2022) (1)
[Functional studies of the autonomic nervous system]. (1993) (1)
SIAXI: IncobotulinumtoxinA for sialorrhea in Parkinson’s disease, stroke, and other etiologies-Phase 3 Results (S30.007) (2018) (1)
Karl Friedrich Bonhoeffer (1957) (1)
The final diagnoses of patients with clinically suspected atypical parkinsonian syndromes. (2021) (1)
Low-dosed botulinum toxin in migraine without aura: A randomized, double-blind placebo-controlled crossover study (2010) (1)
Long-term efficacy and safety of incobotulinumtoxinA treatment for sialorrhea (2018) (1)
Somatosensible Potenziale bei anorektalen Störungen (2006) (1)
[Structure and efferences of the substantia nigra pars compacta in Parkinson's disease]. (2020) (1)
Symptomatic medication of multiple system atrophy with predominant parkinsonism: Overview of 97 patients (2017) (1)
Intra- and interindividual reproducibility of heart rate variations in the tilt-table test. (2000) (1)
[Pharmacotherapy of stress incontinence]. (2005) (1)
The Adult Spasticity International Registry (ASPIRE) study: 1 year results (2017) (1)
The impact of bromocriptine on blood pressure, heart Rate and noradrenaline concentration after active orthostasis in Parkinson patients. (1997) (1)
Should the maximum daily doses of levodopa be limited to 400 mg/die? (2014) (1)
[Botulinumtoxin for bladder disorders]. (2019) (1)
Abstract TMP34: OnabotulinumtoxinA Treatment in Post-stroke Lower Limb Spasticity: Long-term Results From a Phase 3 Study (2016) (1)
Parkinson’s disease – Many diseases with many faces (2008) (1)
Symptomatic medication of 97 patients with multiple system atrophy parkinsonian subtype: An observational study (2018) (1)
Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease. (2014) (1)
[Dystonia Non-Motor Symptoms Questionnaire (DNMSQuest) for assessment of non-motor symptoms in dystonia : Intercultural adaptation in the German language]. (2020) (1)
Botulinumtoxin in the treatment of axillary hyperhidrosis – Longitudinal analysis (2010) (1)
Treatment of dopa-responsive dystonia with Duodopa® (2012) (1)
Principles of Transdermal Drug Delivery Systems for Treatment of Parkinson's Disease (2009) (1)
Electrophysiologic testing of pelvic floor: some remarks. (2002) (1)
How Do I Treat Cervical Dystonia With Botulinum Toxin by Using Ultrasound? (2017) (1)
Ergotamininduzierte Rektumläsionen (1999) (1)
Parkinson’s disease: a multi-faceted disease (2011) (1)
Comment to Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease (2014) (1)
[Autonomic dysregulations in Parkinson's syndrome]. (2005) (1)
[Rational neurologic diagnosis in fecal incontinence]. (1992) (1)
Characterization of advanced Parkinson’s disease in Germany: results of the non-interventional OBSERVE-PD study (2022) (1)
Efficacy of incobotulinumtoxinA in subjects with sialorrhea, assessed using the modified radboud oral motor inventory for Parkinson's disease (mROMP) (2018) (1)
Impact of early intervention with onabotulinumtoxinA treatment in adult patients with post-stroke lower limb spasticity: results from the double-blind, placebo-controlled, phase 3 REFLEX study (2020) (1)
SPECT disclose complementary aspects of Parkinson's disease (2006) (1)
[Help for patients with multiple sclerosis: current diagnostic and treatment possibilities in neurogenic disorders of bladder emptying]. (2008) (1)
AbobotulinumtoxinA for the treatment of upper limb spasticity (2014) (1)
Spasticity in practice (SPACE): an international non-interventional study of botulinum neurotoxin type A in treatment-naïve subjects with spasticity. (2021) (1)
The dopaminergic system: an everlasting challenge. Editorial. (2006) (0)
Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of entacapone: Findings from the real-world OPTIPARK study (2021) (0)
Contents, Vol 34, 1994 (2004) (0)
Workshop III: Late motor complications of Parkinson's disease (2000) (0)
P133 Nonmotor fluctuations in Parkinson’s disease: Evaluation of frequency and severity of nonmotor symptoms in off states of advanced Parkinson’s disease (2011) (0)
Time-course of decline in different cognitive domains in Parkinson’s disease: a retrospective study (2021) (0)
Subject Index Vol. 34, 1994 (1994) (0)
[Adenosine A2A Receptor Antagonists as a Treatment Option for Parkinson's Disease?] (2022) (0)
OnabotulinumtoxinA Reduces Disability in Treatment-Naive Adult Patients with Spasticity: The ASPIRE Study (2019) (0)
NEUROPHYSIOLOGISCHE DIAGNOSTIK IN DER PROKTOLOGIE (1997) (0)
Negative Katalyse und Antiklopfmittel (1941) (0)
Surgical treatment of dystonia (2014) (0)
Comparison of onabotulinumtoxina utilization across various etiologies of spasticity from the Adult spasticity international registry study: ASPIRE (2018) (0)
Management of sialorrhea (2018) (0)
8th Experts Meeting Parkinson's Disease (2007) (0)
Comprehensive Care of Patients with Spastic Paresis – A Long-Term Commitment (2016) (0)
Somatosensory evoked potentials of the pudendal nerve in penile hypoesthesia. Commentary (1998) (0)
[The future of the Parkinson syndrome]. (2010) (0)
Poster 68: IncobotulinumtoxinA for Sustained Improvement in Sialorrhea in Parkinson's Disease, Stroke, and Other Etiologies: Long‐term Results from a Phase 3 Study (2018) (0)
Does botulinum toxin make sense in pain therapy? (2004) (0)
[Treatment of end-of-dose fluctuations: the need for an individualized approach]. (2018) (0)
[Constipation in neurological diseases]. (2000) (0)
Impact of Early Intervention with OnabotulinumtoxinA Treatment in Adult Patients with Post-Stroke Lower Limb Spasticity (S31.006) (2016) (0)
13. Experten Meeting Parkinson (2007) (0)
Botulinum neurotoxin in neurological practice - a leading topic in neurology. (2021) (0)
[Lambert-Eaton syndrome]. (1996) (0)
OnabotulinumtoxinA treatment utilization varies by etiology of spasticity, while maintaining high patient and clinician satisfaction: results from the aspire study (2018) (0)
Attainment of physiologic salivary flow rate with long-term incobotulinumtoxinA treatment for sialorrhea in Parkinson's disease and other neurologic conditions (2020) (0)
[Potential antinociceptive mechanisms of botulinum toxin]. (2006) (0)
Parkinson’s disease—an everlasting challenge (2004) (0)
Drugs in the Treatment of Dystonia, Multisystem Atrophy, and Non-Parkinson Tremor (2020) (0)
First experience with safinamide in clinical practice (2017) (0)
[Complexity of Parkinson Syndrome]. (2016) (0)
Influence of onset of motor fluctuations on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: Findings from the real-world OPTIPARK study (2021) (0)
Incidence of dystonia related to COVID-19 infection. (2023) (0)
Poster 75: Exploring Real‐World OnabotulinumtoxinA Utilization Patterns for the Treatment of Lower Limb Spasticity: The Adult Spasticity International Registry (ASPIRE) Study (2018) (0)
Therapy for Migraine with Almotriptane (2008) (0)
2.249 EFFICACY OF RASAGILINE IN COMBINATION WITH DOPAMINE AGONIST THERAPY: RESULTS FROM A POST-MARKETING OBSERVATIONAL STUDY IN PATIENTS WITH PARKINSON'S DISEASE (2012) (0)
Abstracts Second Congress of the European Society for Clinical Neuropharmacology (1995) (0)
German Guidelines for the Use of Parkinsonian Drugs (2021) (0)
Smoking behavior and idiopathic Parkinson's syndrome (2017) (0)
Early Intervention in Parkinson's Disease with Cabergoline – Results of an Open-Label Long-Term Trial with Focus on Sleep Disturbances (2006) (0)
King’s Parkinson’s Disease Pain Scale--German Version (2019) (0)
Sleep in patients with Parkinson's disease: Differences in two groups of 219 patients with and without sleep disturbances (2017) (0)
[Botulinum toxin in tension-type headache]. (2003) (0)
Time for a change (2016) (0)
[New Therapeutic Options for the Individualised Titration of Levodopa]. (2020) (0)
An international, noninterventional study of botulinum neurotoxin type A in treatment-naive subjects with spasticity (2018) (0)
Baseline Demographics and Clinical Characteristics of Patients Treated for Spasticity in the Adult Spasticity International Registry (ASPIRE Study) (P3.296) (2016) (0)
onabotulinumtoxina treatment in adult patients with post-stroke lower limb spasticity: Results from a double-blind, placebo-controlled, phase 3 clinical trial : o2.2 (2015) (0)
EditorialLate or early treatment in Parkinson's disease? (2013) (0)
Influence of levodopa on orthostatic hypotension in Parkinson's disease (2020) (0)
Poster 66: The Adult Spasticity International Registry (ASPIRE) Study: Treatment Utilization Patterns in Patients Treated for Both Upper and Lower Limb Spasticity (2017) (0)
[Therapy of sialorrhea with botulinum toxin]. (2019) (0)
Individualized onabotulinumtoxinA treatment for upper limb spasticity resulted in high patient and clinician satisfaction in the aspire study (2018) (0)
[Response to the letter by Dr.-H. Zermann on the contribution by W.H. Jost, "Value of electromyography in diagnosis of incontinence"]. (1997) (0)
Poster 471: SIAXI: Efficacy and Safety of IncobotulinumtoxinA for the Treatment of Sialorrhea in Parkinson's Disease (PD), Stroke, and Other Neurological Conditions: Results of a Phase III, Placebo‐Controlled, Randomized, Double‐Blind Study (2017) (0)
Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy (2021) (0)
Is It Meanwhile Biomedical Sciences or Still “Ars Medica”? (2020) (0)
Long-term Efficacy and Safety of IncobotulinumtoxinA Treatment for Sialorrhea (S4.007) (2019) (0)
[Value of electromyography in diagnosis of incontinence]. (1996) (0)
Individualized onabotulinumtoxinA treatment for lower limb spasticity resulted in high patient and clinician satisfaction in the aspire study (2018) (0)
Early Diagnosis in Parkinson’s Disease: Fact or Fiction? (2010) (0)
Treatment of Patients With Upper Limb and Lower Limb Spasticity With OnabotulinumtoxinA in the Adult Spasticity International Registry (ASPIRE) (2022) (0)
Just new problems, or their solution? (2011) (0)
Poster 56: Exploring Real‐World OnabotulinumtoxinA Utilization Patterns for the Treatment of Upper Limb Spasticity: The Adult Spasticity International Registry (ASPIRE) Study (2018) (0)
The SYNAPSES study (StudY to observe SafiNAmide in clinical Practice during the firSt post-commErcialization phaSe): Methodology and feasibility (2017) (0)
Impact of early intervention with onabotulinumtoxinA treatment in adult patients with poststroke lower limb spasticity (2016) (0)
Clinical data on the prolonged-release formulation of ropinirole for Parkinson’s disease (2011) (0)
A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial. (2021) (0)
Rotigotine for Treating Parkinson’s Disease (2020) (0)
An examination of real-world onabotulinumtoxina utilization for the treatment of lower limb spasticity: The Adult Spasticity International Registry (ASPIRE) study (2018) (0)
Cervical dystonia in Parkinson's Disease: frequency of occurrence and subtypes. (2022) (0)
Impulse control disorder and punding arising in a patient treated with levodopa (2010) (0)
1.100 Early diagnosis for Parkinson's disease according to whole blood gene profile (2007) (0)
Neurology meets Psychiatry (2008) (0)
SIAXI: IncobotulinumtoxinA for Sialorrhea in Parkinson's Disease, Stroke, and Other Etiologies-Phase III Results (2017) (0)
[Triple combination of levodopa, carbidopa and entacapone by intrajejunal pump in advanced Parkinson's disease]. (2022) (0)
Are further national Expert Meetings called for today (2014) (0)
[Use of botulinum toxin in urology]. (2008) (0)
2.216 Rasagiline in daily clinical use – a post-marketing observational study in Parkinsonian patients receiving combination therapy shows good efficacy and tolerability (2007) (0)
The influence of relaxation techniques and sports on disability and therapeutic effect in patients with cervical dystonia: Results of an online survey (2017) (0)
[Therapy of Sialorrhea with Botulinum Toxin - An Update]. (2022) (0)
Basal Ganglia and DPG (German Parkinson Society) (2011) (0)
SIAXI: Efficacy and safety of Xeomin (incobotulinumtoxinA) for the treatment of sialorrhea in Parkinson’s disease (PD) and other neurological conditions: Results of a Phase III, placebo-controlled, randomized, double-blind study (S2.007) (2018) (0)
[Neurophysiologic diagnosis in proctology]. (1997) (0)
Rasagiline in Parkinson's disease: the show must go on (2013) (0)
If you can't be with the one you love, love the one you're with (C, S, N & Y) (2023) (0)
Neurophysiological Diagnostics for Anal Incontinence and Constipation (2011) (0)
P155 Clozapine induced parkinsonism: A case report (2011) (0)
Validation of a German version of the NMSS (Non-Motor Symptom assessment Scale) (2010) (0)
MAO-B inhibitors: The questioning never stops (2012) (0)
[20th Experten Meeting Parkinson]. (2020) (0)
Impact of injection guidance techniques on the efficacy and safety of incobotulinumtoxinA for sialorrhea (2018) (0)
Movement Disorders: More than just Parkinson’s disease (2017) (0)
122. Cerebral and extracranial neurodegeneration are strongly coupled in Parkinson’s disease (2009) (0)
Abstracts: Satellite symposium (2005) (0)
OnabotulinumtoxinA Treatment in Patients with Upper Limb and Lower Limb Spasticity from the ASPIRE Study (2021) (0)
1.011 Early diagnosis for Parkinson's disease according to whole blood gene profile (2007) (0)
[Routine diagnosis of disorders of autonomic regulation. References for implementation and evaluation]. (1993) (0)
P154 Dopamine transporter scan in normal pressure hydrocephalus (2011) (0)
[Botulinum toxin in pain therapy]. (2007) (0)
Reply to: Sudden Death In Parkinson´s Disease: Treating Hypertension In The Elderly (2020) (0)
A novel treatment option for intrajejunal levodopa administration (2023) (0)
P107 Piribedil (CLARIUM®) monotherapy in young de-novo patients with Parkinson’s Disease – Subgroup analysis of two prospective, non-interventional observational studies (2011) (0)
Early intervention in parkinson’s disease with cabergoline – Results of an open-label long-term trial with focus on sleep disturbances (2007) (0)
113. Treatment of head tremor with botulinum toxin (2015) (0)
Optimised endoscopic access for intrajejunal levodopa application in idiopathic Parkinson's syndrome. (2023) (0)
Efficacy and safety of incobotulinumtoxinA for the treatment of sialorrhea: Results of the main phase of a phase 3 study (2018) (0)
[Correction: Treatment of Sialorrhea with Botulinum Neurotoxin Type A - Consensus Practice Recommendations for Children and Adults]. (2022) (0)
Somatosensory evoked potentials in neuro-proctology (2006) (0)
Electrophysiologic testing of pelvic floor: Some remarks. Author's reply (2002) (0)
Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of dopamine agonists: Findings from the real-world OPTIPARK study (2021) (0)
Real-World Use of OnabotulinumtoxinA for Lower Limb Spasticity: Adult Spasticity International Registry (ASPIRE) (2018) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Wolfgang H. Jost?

Wolfgang H. Jost is affiliated with the following schools:

Wolfgang H. Jost's Academic­Influence.com Rankings

Wolfgang H. Jost's Degrees

Why Is Wolfgang H. Jost Influential?

Wolfgang H. Jost's Published Works

Published Works

What Schools Are Affiliated With Wolfgang H. Jost?

Wolfgang H. Jost's AcademicInfluence.com Rankings